Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hepatocarcinogenesis in rats treated with several chemicals is associated with changes in
aldehyde dehydrogenase
(AlDH) activity, particularly heterogeneous expression of a "tumor specific" phenotype that is very active with aromatic aldehydes, e.g., benzaldehyde (Bz). Objectives of this study were first, to determine if liver cancers in vinyl chloride-treated rats also expressed this AlDH phenotype, and second, to quantitate the NAD- and NADP-dependent AlDH activity for the substrates Bz and acetaldehyde (Ac) in the cancers and surrounding tissue. Small cubes of tissue containing well-differentiated
hepatocellular carcinoma
were obtained from five Sprague-Dawley rats exposed to 2500 ppm vinyl chloride for 55 weeks. An optimized procedure was developed for AlDH histochemistry. Frozen sections were preincubated in nitroblue tetrazolium/acetone and then incubated at 20 degrees C in viscous polyvinyl alcohol media containing buffer, phenazine methosulfate, sodium azide, substrate, coenzyme, and nitroblue tetrazolium. Background activity was evaluated by omission of substrate. Activity was quantitated by computer-assisted microscopic photometry. All five carcinomas had heterogeneous staining of NADP- and NAD-dependent BzDH and AcDH activity, with clusters of very high-activity cells. The magnitude of staining in the high-activity neoplastic cells was at least tenfold greater for BzDH-NADP and about twofold greater for BzDH-NAD, AcDH-NADP, and AcDH-NAD than the staining in other liver cells. More neoplastic cells had high BzDH than high AcDH activity. Only BzDH-NADP was localized predominantly to the carcinoma.
...
PMID:Quantitative histochemistry of benzaldehyde dehydrogenase in hepatocellular carcinomas of vinyl chloride-treated rats. 300 81
Significant changes in
aldehyde dehydrogenase
(
ALDH
) activity occur during rat hepatocarcinogenesis in vivo. To compare the structure and expression of the tumor
aldehyde dehydrogenase
gene in rat
hepatoma
cell lines and normal rat liver, several rat
hepatoma
cell lines, including HTC, H4-II-EC3, JM2, McA-RH7777, and four lines established in this laboratory have been examined for T-
ALDH
gene expression using a tumor
ALDH
complementary DNA. Northern blot analysis of polyadenylate-containing RNA from log-phase cells and normal rat liver with T-
ALDH
complementary DNA indicates production of a single major 1.7-kilobase transcript in the high activity lines HTC, JM2, RLT-2M, RLT-3C, RLT-9F, and intermediate activity line RLT-5G. There is a direct correlation between expression of T-
ALDH
enzyme activity and the amount of 1.7-kilobase transcript. S1 nuclease protection experiments confirm that there is only one major T-
ALDH
transcript in the high activity lines. Thus, cell line differences in T-
ALDH
activity are reflected in the level of a single T-
ALDH
transcript. Southern analysis was used to identify the T-
ALDH
gene in genomic DNA. The results indicate that no significant amplification or rearrangement of the T-
ALDH
gene has occurred in these
hepatoma
cells. DNA methylation has been proposed to play an important role in gene expression. Genomic DNA from HTC, JM2, McA-RH7777, H4-II-EC3, RLT-2M, RLT-9F, RLT-3C, RLT-5G, rat embryo and normal rat liver were digested with MspI and HpaII to examine methylation patterns. A digestion pattern consistent with hypomethylation was detected only in DNA from the high T-
ALDH
activity cell lines HTC, JM2, RLT-2M, and RLT-9F. This suggests that constitutive expression of T-
ALDH
in the
hepatoma
cells is related to changes in DNA methylation patterns.
...
PMID:Expression of tumor-associated aldehyde dehydrogenase gene in rat hepatoma cell lines. 326 98
The cytosolic
aldehyde dehydrogenase
(
ALDH
) isozyme from cyclophosphamide (CPA) resistant L1210 cells (L1210/CPA) was purified to apparent homogeneity using ternary enzyme complex-dye ligand chromatography. The purified isozyme migrates as a single band at Mr 51,000 in sodium dodecyl sulfate polyacrylamide gel electrophoresis and as a single charge species at isoelectric point = 5.8 in isoelectric focusing. Micromolar Km values were estimated with both propionaldehyde (Km = 5 microM) and 4-hydroxy cyclophosphamide (4-OH CPA) (Km = 4 microM) as substrates, indicating that this isozyme is capable of oxidizing the activated cyclophosphamide intermediate 4-hydroxy CPA/aldophosphamide to carboxyphosphamide. This isozyme is also potently inhibited by disulfiram (Ki = 6 microM) and 4-(diethylamino)benzaldehyde (Ki = 0.04 microM). Both of these inhibitors are capable of sensitizing L1210/CPA cells to activated CPA in clonogenic survival assays. Thus, the increased levels of only the cytosolic
ALDH
isoform in L1210/CPA cells appear to be the single phenotypic difference necessary for conferring resistance to CPA. Monospecific antibodies to the L1210/CPA isozyme have been used in Western blot analysis to detect nanogram levels of
ALDH
in cell and tissue extracts. These antibodies cross-react with the cytosolic isozyme in P388/CPA cells, mouse liver, mouse small intestine, and the 1C1C7
hepatoma
cell line, whereas no
ALDH
is detected in sensitive L1210 or P388 cells. Also, these antibodies show little cross-reactivity with the mitochondrial isozyme from mouse liver or 1C1C7 cells. From immunological and inhibitor characterization, the soluble
ALDH
isozyme in L1210/CPA cells appears identical to the normal mouse tissue isozyme.
...
PMID:Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. 336 87
We have proposed developing rat
hepatoma
cell lines as an in vitro model for studying the regulation of changes in
aldehyde dehydrogenase
activity occurring during hepatocarcinogenesis. Aldehyde dehydrogenase purified in a single step from HTC rat
hepatoma
cells is identical to the
aldehyde dehydrogenase
isolated from rat hepatocellular carcinomas. HTC
aldehyde dehydrogenase
is a 100 kDa dimer composed of 54-kDa subunits, prefers NADP+ as coenzyme, and preferentially oxidizes benzaldehyde-like aromatic aldehydes but not phenylacetaldehyde. The substrate and coenzyme specificity, effects of disulfiram, pH profile and isoelectric point of HTC
aldehyde dehydrogenase
are also identical to these same properties of the tumor
aldehyde dehydrogenase
. In immunodiffusion, both isozymes are recognized with complete identity by anti-HTC
aldehyde dehydrogenase
antibodies. Having established that HTC
aldehyde dehydrogenase
is very similar, if not identical, to the
aldehyde dehydrogenase
found in hepatocellular carcinomas, simplifies the development of molecular probes for examination of the regulation of tumor
aldehyde dehydrogenase
activity in vivo and in vitro.
...
PMID:Characterization of aldehyde dehydrogenase from HTC rat hepatoma cells. 393 72
The cytosolic
aldehyde dehydrogenase
was isolated from the liver of Wistar rats treated with phenanthrene (non-carcinogenic) or benzo[a]pyrene (carcinogenic polycyclic aromatic hydrocarbon). The benzo[a]pyrene-induced enzyme has higher Km values for small aliphatic aldehydes and a lower molecular weight than the phenanthrene-induced enzyme. It is more resistant to changes of pH and to inhibition by disulfiram, but more sensitive to heat denaturation than the phenanthrene-induced enzyme. The phenanthrene-induced
aldehyde dehydrogenase
is very similar to the normal uninduced
aldehyde dehydrogenase
, whereas the benzo[a]pyrene-induced
aldehyde dehydrogenase
has common properties with the TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin)-induced enzyme and the
hepatoma
-specific enzyme.
...
PMID:Isolation and characterization of rat liver cytosolic aldehyde dehydrogenases induced by phenanthrene or benzo[a]pyrene. 399 24
Aldehyde dehydrogenase subcellular distribution and activity were studied in the Yoshida
hepatoma
AH-130 and rat liver. NAD+- and NADP+-dependent dehydrogenase activities were lower in all
hepatoma
subfractions (except the cytosol) than in liver subfractions. In the presence of 0.025 mM substrate 78-80% of the liver NAD+- or NADP+-dependent aldehyde dehydrogenase was found in the mitochondria. With 10 mM substrate the enzyme activity was primarily in the mitochondria and microsomes. In the
hepatoma
a sharp increase of the soluble
aldehyde dehydrogenase
(either NAD+- or NADP+ dependent) was observed at all substrate concentrations. The Km of the different isoenzymes (either identified by their localization or coenzyme dependency) were of the same order for liver and
hepatoma
. However, a high Km enzyme was present in liver mitochondria outer membranes but not in
hepatoma
.
Hepatoma
acetaldehyde dehydrogenase was inhibited, as was the liver enzyme, by diethyldithiocarbamate. The return of activity was slower for the
hepatoma
and neonatal liver than for the adult liver enzyme.
...
PMID:The subcellular distribution and properties of aldehyde dehydrogenase of hepatoma AH-130. 630 66
The effect of separate and combined administration of 15% ethanol and 0.2% CsCl solution on life span of rats with Novikoff
hepatoma
implants was studied as a function of time of initiation of treatment. Pretreatment with CsCl alone or combined with ethanol resulted in earlier onset on morbidity compared to the ethanol-treatment or to controls. As high as 87.5% of Cs-treated animals died 16 days post tumor implantation compared to 33% of rats receiving CsCl and ethanol combined. This protective action of ethanol against Cs-evoked toxicity in tumor-bearing rats persisted through the experiment. Animals subjected to drug treatment immediately after tumor transplantation displayed delayed onset of morbidity compared to drug pretreated rats. In both cases the Cs-treatment enhanced morbidity by approximately 2 folds from corresponding controls. Animals sacrificed 18 days post tumor inoculation showed an induction of hepatic alcohol dehydrogenase and an increase in Vmax without changes in the apparent Km by the Cs-treatment. There was an increase in liver mitochondrial
aldehyde dehydrogenase
of
hepatoma
-bearing rats from tumor-free controls which was associated with an increase in the apparent Km value. The results indicate potentiation of the
hepatoma
toxicity by CsCl which may be minimized by ethanol. A role for hepatic enzymes determined in the pathogenesis of tumor line studied and/or their use as a biochemical correlate is suggested.
...
PMID:Effect of cesium and ethanol on tumor bearing rats. 639 34
The interrelationship between certain dehydrogenases and a hepatic tumor was studied in mice. A rapidly growing
hepatoma
, Novikoff
hepatoma
, was transplantable from rats to mice after serial passages in Sprague-Dawley albino mice. Mice inoculated with viable tumor cell suspension were sacrificed 14, 18, 21 or 34 days thereafter. Hepatic cytoplasmic and mitochondrial
aldehyde dehydrogenase
(
ALDH
) were measured in addition to liver alcohol dehydrogenase (ADH) and testicular
ALDH
. Hepatic cytoplasmic and mitochondrial
ALDH
were markedly inhibited from controls at all time periods studied. Likewise, testicular
ALDH
was inhibited from respective controls in Novikoff
hepatoma
-bearing mice. No changes were measurable in hepatic ADH of
hepatoma
-bearing mice. The enzyme kinetics studied show a reduction in Vmax and an alteration in the apparent Km 34 days after tumor inoculation. Further analyses of hepatic mitochondrial
ALDH
showed that the inhibition was similarly present in the enzyme with the low and the high Km property. The results suggest that changes in the specific activity and property of
ALDH
may be a useful tool as a biochemical concomitant to both development and progression of the
hepatoma
studied.
...
PMID:Hepatic and testicular aldehyde dehydrogenase in tumor-bearing mice. 639 79
Significant changes in
aldehyde dehydrogenase
(
ALDH
) activity occur during rat hepatocarcinogenesis in vivo. An NADP-dependent tumor
ALDH
isozyme has been studied extensively. To better understand the nature, origin, and importance of this tumor-associated phenotypic change, we have examined the
ALDH
activity of five well-established rat
hepatoma
cell lines, H4-II-EC3, HTC, McA-RH7777, JM1, and JM2. HTC, JM1, and JM2 express the tumor
ALDH
phenotype, as indicated by elevated NADP-dependent, benzaldehyde-oxidizing activity, the appearance of new isozymes by electrophoresis, and characteristic histochemical localization of
ALDH
activity in situ. The tumor
ALDH
phenotype is not detected in McA-RH7777 cells. H4-II-EC3 has intermediate tumor
ALDH
activity. Thus, the 5 cell lines provide a spectrum of tumor
ALDH
activities representative of the range of activities seen in vivo. Benzo(a)pyrene, 3-methylcholanthrene, and phenobarbital induce hepatic
ALDH
activity after treatment in vivo. The ability of these compounds to induce
ALDH
in vitro was assessed in H4-II-EC3, McA-RH7777, HTC, JM1, and JM2. Treatment of cell cultures for 72 hr with 3-methylcholanthrene (1.0 mM) increases the NADP-dependent
ALDH
activity in H4-II-EC3 and McA-RH7777 cell lines up to 34- and 11-fold, respectively. Treatment with benzo(a)pyrene (1.0 mM) also increases the NADP-dependent
ALDH
activity in both lines up to 17- and 48-fold, respectively. Treatment with 3-methylcholanthrene or benzo(a)pyrene increases
ALDH
activity 2-fold in HTC and JM2 but does not increase NADP-dependent
ALDH
activity in JM1. Only marginal increases in NADP-dependent
ALDH
are observed after phenobarbital treatment in 4 of 5 cell lines. The induction of
ALDH
is blocked by actinomycin D, alpha-amanitin, and cycloheximide. These studies support our hypothesis that changes in
ALDH
activity observed in vivo are due to mutational events occurring in initiated cells. It appears that rat
hepatoma
cell lines will provide an in vitro model for studying genetic regulation of the tumor
ALDH
.
...
PMID:Regulation of aldehyde dehydrogenase activity in five rat hepatoma cell lines. 648 82
In aromatic amine-induced rat hepatomas, the
aldehyde dehydrogenase
(AIDH) phenotype is qualitatively and quantitatively different from that of normal liver. To identify the mechanism(s) underlying the expression of the tumor-specific AIDHs, we have followed the time course of appearance of the new phenotype during
hepatoma
formation in Sprague-Dawley rats following brief dietary exposures to 2-acetylaminofluorene (0.02%; 32 days). Tumor promotion by phenobarbital (0.05% in the diet) was also used to compare the effects of a variety of tumor induction protocols on the AIDH phenotype. No change in the AIDH phenotype is detectable by total activity assay, gel electrophoresis, isoelectric focusing, or immunochemical methods during or following exposure to carcinogen or promoter until tumors are grossly observed in liver. Concomitant with tumor appearance, the tumor-specific AIDH phenotype appears. The phenotypic change is limited to the tumor; morphologically and histologically normal liver directly adjacent to the tumor and normal lobes of a tumor-bearing liver do not possess the tumor AIDH phenotype. No correlation exists between tumor size and the degree of deviation of the AIDH phenotype from normal. Nor is there any correlation between the degree of AIDH phenotype deviation and the histology of the various tumors observed. We conclude that the tumor-specific AIDH phenotype is not associated with altered liver metabolism due directly to carcinogen or promoter exposure. Rather, the mechanism of this phenotypic change requires that transformation-associated, stable genetic changes occur in the cells affected by carcinogen that are later expressed as the altered AIDH phenotype.
...
PMID:Expression of the tumor aldehyde dehydrogenase phenotype during 2-acetylaminofluorene-induced rat hepatocarcinogenesis. 705 5
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>